Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
Author(s) -
Howard I. Scher,
Susan Halabi,
Ian F. Tannock,
Michael J. Morris,
Cora N. Sternberg,
Michael A. Carducci,
Mario A. Eisenberger,
Celestia S. Higano,
Glenn J. Bubley,
Robert Dreicer,
Daniel Petrylak,
Philip W. Kantoff,
Ethan Basch,
William Kevin Kelly,
William D. Figg,
Eric J. Small,
Tomasz M. Beer,
George Wilding,
Alison Martin,
Maha Hussain
Publication year - 2008
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2007.12.4487
Subject(s) - medicine , prostate cancer , clinical trial , cancer , disease , prostate , response evaluation criteria in solid tumors , oncology , prostate specific antigen , progressive disease
To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom